GSK PLC announced on Wednesday that its sales in the fiscal year 2024 saw a yearly growth of 7% at the Constant Exchange Rate to reach £31.4 billion. On the other hand, its operating profit decreased by 33% compared to the previous year to land at £4 billion. The earnings per share (EPS) declined by 40% year-on-year to 63.2 pence.
"Our outperformance and stronger balance sheet support these investments [in Respiratory, Immunology & Inflammation, Oncology and HIV] and others planned in R&D [research and development], as well as the opportunity to enhance shareholder returns through our progressive dividend and the share buyback program which we have set out today," Chief Executive Officer (CEO) Emma Walmsley commented.
Additionally, the pharmaceutical company predicted its sales to rise by between 3% and 5% in 2025, core operating profit by between 6% and 8%, and core EPS between 6% and 8%.
